Emergent Biosolutions (EBS) to Release Earnings on Wednesday

Key Points

• Emergent Biosolutions is set to release its Q3 2025 earnings on October 29, 2025, with analysts forecasting an earnings per share of ($0.01) and revenue of approximately $203.67 million.
• The company's stock, which recently opened at $9.46, experienced a decline of 3.8% and has a market cap of $504.69 million, with a notable 52-week low of $4.02 and high of $12.73.
• Analyst ratings for Emergent Biosolutions show a consensus of "Hold" with a target price of $13.50, while there has been recent insider selling from directors, indicating potential caution amid shifts in ownership.

Emergent Biosolutions (NYSE:EBS - Get Free Report) is projected to post its Q3 2025 results after the market closes on Wednesday, October 29th. Analysts expect Emergent Biosolutions to post earnings of ($0.01) per share and revenue of $203.6670 million for the quarter. Emergent Biosolutions has set its FY 2023 guidance at EPS.Individuals can check the company's upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 5:00 PM ET.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last announced its quarterly earnings data on Tuesday, January 9th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter. Emergent Biosolutions had a net margin of 16.38% and a return on equity of 24.63%. The business had revenue of $222.50 million during the quarter. On average, analysts expect Emergent Biosolutions to post $-1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Emergent Biosolutions Trading Down 3.8%

Shares of EBS stock opened at $9.46 on Wednesday. Emergent Biosolutions has a 52-week low of $4.02 and a 52-week high of $12.73. The stock has a market cap of $504.69 million, a price-to-earnings ratio of 3.86 and a beta of 2.04. The company has a debt-to-equity ratio of 1.25, a quick ratio of 3.00 and a current ratio of 5.66. The firm has a fifty day moving average of $8.73 and a 200-day moving average of $7.06.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Wall Street Zen cut shares of Emergent Biosolutions from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. Weiss Ratings reiterated a "sell (d)" rating on shares of Emergent Biosolutions in a research report on Wednesday, October 8th. Finally, HC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of Emergent Biosolutions in a research report on Wednesday, September 3rd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $13.50.

Insider Buying and Selling

In related news, Director Kathryn C. Zoon sold 7,086 shares of the stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $8.87, for a total transaction of $62,852.82. Following the completion of the sale, the director owned 71,799 shares in the company, valued at $636,857.13. This trade represents a 8.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Donald W. Degolyer sold 7,844 shares of the stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $8.65, for a total transaction of $67,850.60. Following the sale, the director owned 137,659 shares of the company's stock, valued at $1,190,750.35. This trade represents a 5.39% decrease in their position. The disclosure for this sale can be found here. Insiders sold 45,538 shares of company stock worth $436,783 in the last quarter. 3.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Emergent Biosolutions

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc acquired a new stake in Emergent Biosolutions in the 2nd quarter valued at about $31,000. Brevan Howard Capital Management LP increased its position in Emergent Biosolutions by 44.2% in the 2nd quarter. Brevan Howard Capital Management LP now owns 18,724 shares of the biopharmaceutical company's stock valued at $119,000 after acquiring an additional 5,743 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in Emergent Biosolutions in the 2nd quarter valued at about $53,000. State of Wyoming increased its position in Emergent Biosolutions by 32.5% in the 2nd quarter. State of Wyoming now owns 41,315 shares of the biopharmaceutical company's stock valued at $264,000 after acquiring an additional 10,127 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new stake in Emergent Biosolutions in the 2nd quarter valued at about $115,000. Institutional investors and hedge funds own 78.40% of the company's stock.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.